Home›Clinical trials›Colorado

GLP-1 clinical trials in Colorado: 18 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

18 GLP-1 clinical trials are recruiting at 21 sites in 4 cities across Colorado. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Colorado

  1. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    2 sites in Colorado

  2. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    2 sites in Colorado

  3. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    2 sites in Colorado

    • University of Colorado Anschutz Medical Campus, Aurora. 303-724-4651
    • South Denver Gastroenterology, Englewood

  4. Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

    Phase 3. Run by University of Colorado, Denver. Registry number NCT05819138.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 1 diabetes lower blood sugar.

    Who can join. Adults 18 to 49, have type 1 diabetes, BMI 20+.

    1 site in Colorado

    • University of Colorado Anschutz Medical Campus, Aurora. 720-777-9500

  5. Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

    Phase 3. Run by University of Colorado, Denver. Registry number NCT05819853.

    A study testing whether a GLP-1 medicine, semaglutide, can help people manage PCOS.

    Who can join. Ages 12 to 35, women only, have polycystic ovary syndrome (PCOS), BMI 27+.

    1 site in Colorado

    • University of Colorado Anschutz/Children's Hospital Colorado Aurora, Aurora. 720-777-6984

  6. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Colorado

    • Children's Hospital Colorado, Colorado Springs

  7. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in Colorado

  8. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07202884.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    1 site in Colorado

  9. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07223593.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    1 site in Colorado

    • Rocky Mountain Regional VA Medical Center, Aurora

  10. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in Colorado

    • University of Colorado Hospital, Aurora

  11. GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

    Phase 2. Run by University of Pennsylvania. Registry number NCT04731272.

    A study testing whether a GLP-1 medicine, dulaglutide, can help people with cystic fibrosis lower blood sugar.

    Who can join. Adults 18+, have cystic fibrosis, BMI 19+.

    1 site in Colorado

  12. Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

    Phase 2. Run by University of Washington. Registry number NCT05822609.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with diabetic kidney disease protect their kidneys.

    Who can join. Adults 18+, have diabetic kidney disease, BMI 20+.

    1 site in Colorado

    • University of Colorado Anschutz Medical Campus, Aurora. 720-689-4751

  13. Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

    Phase 2. Run by University of Colorado, Denver. Registry number NCT06582875.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with polycystic kidney disease protect their kidneys.

    Who can join. Adults 18 to 65, have polycystic kidney disease, BMI 27+.

    1 site in Colorado

    • University of Colorado - Anschutz Medical Campus, Aurora. 303-724-4842

  14. A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT06717698.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    1 site in Colorado

    • Rocky Mount Reg VA Med-DN, Aurora

  15. Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

    Phase 2. Run by University of Colorado, Denver. Registry number NCT06975111.

    A study of a GLP-1 medicine, semaglutide, in women going through menopause.

    Who can join. Adults 45 to 55, women only, are going through menopause.

    1 site in Colorado

    • University of Colorado-School of Medicine, Aurora

  16. Multi-Site Trial of Tirzepatide for Smoking Cessation

    Phase 2. Run by University of Southern California. Registry number NCT07602699.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people quit smoking.

    Who can join. Adults 21 to 65, are trying to quit smoking, BMI 25+.

    1 site in Colorado

    • University of Colorado Anschutz Medical Campus, Aurora. 303-724-3196

  17. Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

    Phase 1. Run by University of Colorado, Denver. Registry number NCT06575738.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with obesity lose weight.

    Who can join. Ages 12 to 24, have obesity.

    1 site in Colorado

  18. Effects of GLP-1 RAs on Human Lactation Outcomes

    Run by University of Colorado, Denver. Registry number NCT07720414.

    A study of a GLP-1 and GIP medicine, tirzepatide.

    Who can join. Adults 18+, women only.

    1 site in Colorado

    • University of Colorado Anschutz School of Medicine, Aurora

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.